Journal
IMMUNOTHERAPY
Volume 14, Issue 7, Pages 521-530Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2022-0027
Keywords
COVID-19; EGFR; fibrosis; inflammation; monoclonal antibody; nimotuzumab; SARS-CoV-2
Categories
Funding
- Cuban Ministry of Health
- Center of Molecular Immunology
Ask authors/readers for more resources
This study evaluated the safety and efficacy of nimotuzumab in COVID-19 patients. The results showed that nimotuzumab is a safe antibody that can reduce inflammation and prevent fibrosis.
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in the national guideline. Results: 41 patients (31 severe and 10 moderate) received nimotuzumab. The median age was 62 years and the main comorbidities were hypertension, diabetes and cardiovascular disease. The antibody was very safe and the 14-day recovery rate was 82.9%. Inflammatory markers decreased over time. Patients did not show signs of fibrosis. Conclusion: Nimotuzumab is a safe antibody that might reduce inflammation and prevent fibrosis in severe and moderate COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available